243 related articles for article (PubMed ID: 33636142)
1. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.
Shouval R; Fein JA; Labopin M; Cho C; Bazarbachi A; Baron F; Bug G; Ciceri F; Corbacioglu S; Galimard JE; Giebel S; Gilleece MH; Giralt S; Jakubowski A; Montoto S; O'Reilly RJ; Papadopoulos EB; Peric Z; Ruggeri A; Sanz J; Sauter CS; Savani BN; Schmid C; Spyridonidis A; Tamari R; Versluis J; Yakoub-Agha I; Perales MA; Mohty M; Nagler A
Lancet Haematol; 2021 Mar; 8(3):e205-e215. PubMed ID: 33636142
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies.
Ciurea SO; Kongtim P; Hasan O; Ramos Perez JM; Torres J; Rondon G; Champlin RE
Clin Cancer Res; 2020 May; 26(10):2404-2410. PubMed ID: 32019857
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
Sharma A; Bhatt NS; St Martin A; Abid MB; Bloomquist J; Chemaly RF; Dandoy C; Gauthier J; Gowda L; Perales MA; Seropian S; Shaw BE; Tuschl EE; Zeidan AM; Riches ML; Shah GL
Lancet Haematol; 2021 Mar; 8(3):e185-e193. PubMed ID: 33482113
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.
He F; Cao Q; Lazaryan A; Brunstein C; Holtan S; Warlick E; Ustun C; McClune B; Arora M; Rashidi A; Eckfeldt C; Weisdorf DJ; Bejanyan N
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1485-1490. PubMed ID: 28522345
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
7. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
Paviglianiti A; Ruggeri A; Volt F; Sanz G; Milpied N; Furst S; Esquirol A; Arcese W; Picardi A; Ferra C; Ifrah N; Bourhis JH; Raj K; von dem Borne PA; Sica S; Menard AL; Bloor A; Kenzey C; Gluckman E; Rocha V
Br J Haematol; 2017 Dec; 179(5):790-801. PubMed ID: 29048109
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract][Full Text] [Related]
12. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Gagelmann N; Eikema DJ; Stelljes M; Beelen D; de Wreede L; Mufti G; Knelange NS; Niederwieser D; Friis LS; Ehninger G; Nagler A; Yakoub-Agha I; Meijer E; Ljungman P; Maertens J; Kanz L; Lopez-Corral L; Brecht A; Craddock C; Finke J; Cornelissen JJ; Bernasconi P; Chevallier P; Sierra J; Robin M; Kröger N
Haematologica; 2019 May; 104(5):929-936. PubMed ID: 30655377
[TBL] [Abstract][Full Text] [Related]
13. Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation.
Kaito S; Wada A; Adachi H; Konuma R; Kishida Y; Nagata A; Konishi T; Yamada Y; Kumagai T; Yoshifuji K; Mukae J; Akiyama M; Inamoto K; Toya T; Igarashi A; Najima Y; Muto H; Kobayashi T; Kakihana K; Ohashi K; Sakamaki H; Doki N
Ann Hematol; 2020 Jul; 99(7):1655-1665. PubMed ID: 32524200
[TBL] [Abstract][Full Text] [Related]
14. Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study.
Gadalla SM; Wang Y; Wang T; Onabajo OO; Banday AR; Obajemu A; Karaesman E; Sucheston-Campbell L; Hahn T; Sees JA; Spellman SR; Lee SJ; Katki HA; Prokunina-Olsson L
Lancet Haematol; 2020 Oct; 7(10):e715-e723. PubMed ID: 32976751
[TBL] [Abstract][Full Text] [Related]
15. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
16. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study.
Chapchap EC; Kerbauy LN; Esteves I; Belucci TR; Rodrigues M; Kerbauy FR; de Souza Santos FP; Ribeiro AAF; Hamerschlak N
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13122. PubMed ID: 31257689
[TBL] [Abstract][Full Text] [Related]
18. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
20. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
Sant M; Minicozzi P; Mounier M; Anderson LA; Brenner H; Holleczek B; Marcos-Gragera R; Maynadié M; Monnereau A; Osca-Gelis G; Visser O; De Angelis R;
Lancet Oncol; 2014 Aug; 15(9):931-42. PubMed ID: 25030467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
